ARTIVION, INC.
Artivion develops, manufactures, processes and distributes medical devices and implantable human tissues used mainly by cardiac and vascular surgeons to treat patients with aortic disease. Its two reportable segments are Medical Devices, which includes aortic stent grafts, surgical sealants, On-X products and other products, and Preservation Services, which preserves cardiac and vascular tissues for implantation. Its product families include aortic stent grafts, On-X mechanical heart valves and related surgical products, BioGlue surgical sealants, and human tissues such as CryoValve, CryoPatch, CryoVein and CryoArtery. It also sells or distributes products including PhotoFix bovine surgical patches. Artivion makes money by selling medical devices and related products and by providing tissue-preservation services. Its stent graft portfolio includes products for aortic arch, thoracic, thoraco-abdominal and abdominal disease; On-X products include heart valves, an ascending aortic prosthesis, catheters, sutures and carbon coating services. Artivion is headquartered in Kennesaw, Georgia.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AORT in the last 30 days.
See all $AORT insider activity →Citizens kept Artivion's rating at Market Outperform but reduced its price target to $42 from $48, a 12.5% cut. This implies a 65.8% upside from its Nov 5 close of $25.33, according to the firm.
Artivion (AORT) reported Q3 2026 revenue of $123.8M, up 9% YoY. Stent graft revenues grew 12%, On-X grew 13%, while tissue processing and BioGlue saw slight declines. Adjusted EBITDA decreased 8% to $22.5M. The company expects U.S. commercial launch of NEXUS in early 2027 and FDA approval for ARCEVO LSA in 2029, unlocking an $80M opportunity. Gross margins fell to 61.4% due to mix and manufacturing investments. Free cash flow was negative $17.6M.
Artivion reported Q3 2026 revenue of $123.8M, up 9% YoY, with a net loss of $7.9M. Adjusted EBITDA declined 8% to $22.5M. CEO Pat Mackin highlighted growth in On-X and stent grafts, and progress in product launches. The company narrowed its 2026 revenue outlook to $484M-$492M, with adjusted EBITDA expected between $93M-$98M.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning AORT (ARTIVION, INC.). Coverage has skewed bearish: 1 bullish, 2 neutral, and 7 bearish.
Recent AORT coverage spans earnings, market movers and insider activity.
Citizens kept Artivion's rating at Market Outperform but reduced its price target to $42 from $48, a 12.5% cut. This implies a 65.8% upside from its Nov 5 close of $25.33, according to the firm.
Earnings show top-line growth but margin compression, suggesting modest downside risk.
Earnings miss and narrowed outlook may weigh on the stock.
Sector-wide risk-on move likely dominates, with limited evidence of an AORT-specific new catalyst.
Artivion, Inc. will release its Q3 2026 financial results after market close on Nov. 5, followed by a teleconference at 4:30 p.m. ET. The company's products include aortic stent grafts, surgical sealants, and heart valves. A replay and webcast will be available post-event. Artivion operates in over 100 countries. The earnings press release will be on the company's website.
AlphAI scores every news story that mentions AORT with an AI model for sentiment and relevance, and aggregates insider trades from ARTIVION, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Citizens kept Artivion's rating at Market Outperform but reduced its price target to $42 from $48, a 12.5% cut. This implies a 65.8% upside from its Nov 5 close of $25.33, according to the firm.
Artivion (AORT) reported Q3 2026 revenue of $123.8M, up 9% YoY. Stent graft revenues grew 12%, On-X grew 13%, while tissue processing and BioGlue saw slight declines. Adjusted EBITDA decreased 8% to $22.5M. The company expects U.S. commercial launch of NEXUS in early 2027 and FDA approval for ARCEVO LSA in 2029, unlocking an $80M opportunity. Gross margins fell to 61.4% due to mix and manufacturing investments. Free cash flow was negative $17.6M.
Artivion reported Q3 2026 revenue of $123.8M, up 9% YoY, with a net loss of $7.9M. Adjusted EBITDA declined 8% to $22.5M. CEO Pat Mackin highlighted growth in On-X and stent grafts, and progress in product launches. The company narrowed its 2026 revenue outlook to $484M-$492M, with adjusted EBITDA expected between $93M-$98M.
Shares of Stryker, Omnicell, Zimmer Biomet, Artivion, and Dentsply Sirona surged after Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing. Analysts expect the biopharmaceutical sector to strengthen. Stryker (SYK) rose 8.8%, Omnicell (OMCL) 10.8%, Zimmer Biomet (ZBH) 15.2%, Artivion (AORT) 9.1%, and Dentsply Sirona (XRAY) 9.2%. Zimmer Biomet's shares hit a 52-week high of $111.96.
Artivion, Inc. will release its Q3 2026 financial results after market close on Nov. 5, followed by a teleconference at 4:30 p.m. ET. The company's products include aortic stent grafts, surgical sealants, and heart valves. A replay and webcast will be available post-event. Artivion operates in over 100 countries. The earnings press release will be on the company's website.
Artivion Inc (NYSE:AORT) shares rose 4.2% after Jefferies initiated coverage with a Buy rating and $31 price target. The firm cited the company's expanding product pipeline, expected double-digit revenue growth, and expanding profit margins. Jefferies forecasts $547M and $617M in revenue for 2027 and 2028, respectively, above consensus. The stock is seen as undervalued relative to peers, offering an attractive entry point ahead of commercial catalysts.
Merit Medical (MMSI) reported Q2 revenue growth of 9%, raising full-year guidance and seeing a 4.5% stock increase. ICU Medical (ICUI) reported flat revenue but beat EPS estimates, with a 2.1% stock decline. Penumbra (PEN) saw 14.9% revenue growth but missed EPS estimates, with a flat stock. Artivion (AORT) reported 11.3% revenue growth and beat EPS estimates, but its stock fell 19.2%.
Artivion Inc. (AORT) reported Q2 2026 revenue growth of 11% to $125.8M, driven by its aortic arch portfolio. However, it posted a net loss of $13.5M, reversing from a profit a year earlier. The company completed the Endospan acquisition and received FDA approval for AMDS. Despite growth, profitability declined, and guidance was reiterated without an increase.
GREEN ANDREW M (SVP, Regulatory and Quality) sold 11,480 shares of ARTIVION, INC. (AORT) at $24.97 ($0.29M total) on 2026-09-10.
GREEN ANDREW M (SVP, Regulatory and Quality) sold 8,003 shares of ARTIVION, INC. (AORT) at an average of $27.03 ($26.02–$27.26, $0.22M total) across 2 trades over 2026-09-02 to 2026-09-03.
